Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 9Lymphoma, T-Cell, Cutaneous 6Lymphoma, T-Cell 6Lymphoma 6Sezary Syndrome 3Mycosis Fungoides 3Multiple Myeloma 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Oligodendroglioma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Malignant mesenchymal tumor 1

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrence × romidepsin × Clear all
NCT02341014 2024-04-04

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
27 enrolled 13 charts
Lymphoid

Lymphoma, Recurrence, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡